Results 111 to 120 of about 6,337 (198)

Current Antiviral Options for Therapeutic Management Of SARS-CoV-2 Infection [PDF]

Introduction: The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent need for effective antiviral treatments.
Riego, Nyka Rane
core   +1 more source

Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis

Journal of Infection in Developing Countries
Introduction: Paxlovid (nirmatrelvir/ritonavir) is a new oral antiviral drug that is used for coronavirus disease 2019 (COVID-19) and is administered to patients with mild to moderate disease for five consecutive days.
Yu Wang, Yuya Yang, Rong Shan, Liangfeng Zhao, Yanyan Bai, Liuliu Feng   +5 more
doaj   +1 more source

Exploring early COVID-19 therapies, variants, and viral clearance dynamics: Insights from a high-risk outpatients study

This retrospective observational study investigates the impact of early COVID-19 therapies, including antivirals and monoclonal antibodies (mAbs), on time to achieve negative swab results in high-risk outpatients infected with specific Omicron ...
Bergna, Annalisa, Colaneri, Marta, Fassio, Federico, Galli, Lucia, Gori, Andrea, Lai, Alessia, Matone, Maddalena, Scaglione, Giovanni, Schiavini, Monica, Ventura, Carla della   +9 more
core   +2 more sources

Exploring The Inhibition of SARS-COV-2 PLpro: Docking and Molecular Dynamics Simulation of Flavonoid in Red Fruit Papua and Its Derivatives [PDF]

In early 2024, Covid-19 witnessed a substantial decline in cases. Nevertheless, with lingering cases and fatalities persisting, it remains crucial to focus on research to develop patented medicines to inhibit the spread of this virus effectively.
Ananto, Agus Dwi, Haryadi, Winarto, Pranowo, Harno Dwi, Prasetyo, Niko   +3 more
core   +2 more sources

Outcome differences of starting Paxlovid for COVID-19 within or after five days of symptoms onset in the elderly: a retrospective study

Journal of Infection in Developing Countries
Introduction: The study aimed to compare the outcomes of nirmatrelvir and ritonavir drug combination (Paxlovid) therapy in patients who received treatment within or after five days of COVID-19 confirmed in the elderly.
Junjun Chen, Quanjun Yang, Xiaohong Xu, Xia Wu, Yonglong Han, Cheng Guo, Jiao Yang   +6 more
doaj   +1 more source

The problem of SARS-CoV-2 virus resistance to direct-acting antivirals

Биопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. The high prevalence of mutations in the SARS-CoV-2 genome raises particular concerns about the resistance of the virus to current antiviral therapy, including inhibitors of the main protease, or 3C-like protease (3CLpro), and RNA-dependent ...
E. L. Gasich, E. N. Krotkova, A. D. Kasko, K. Yu. Bulda, A. G. Krasko, E. A. Dorofeeva, I. A. Karpov   +6 more
doaj   +1 more source

COVID-19 rebound after Paxlovid treatment [PDF]

Distributed via the CDC Health Alert NetworkMay 24, 2022, 9:00 AM ETCDCHAN-0467The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and ...

core  

Nirmatrelvir: from discovery to modern and alternative synthetic approaches [PDF]

The global urgency in response to the COVID-19 pandemic has catalyzed extensive research into discovering efficacious antiviral compounds against SARS-CoV-2.
Alessandra Silvani, Andrea Citarella, Daniele Passarella, Francesco Migliano, Michela Galli, Valerio Fasano   +5 more
core   +1 more source

Interim clinical considerations for COVID-19 treatment in outpatients [PDF]

Updated June 15, 2022This page provides a treatment overview for healthcare providers ...

core  

Québec authorizes pharmacists to prescribe Paxlovid

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources